Anti-TROP2 protein monoclonal antibody as well as preparation method and application thereof
By developing rabbit monoclonal antibodies with high specificity and sensitivity, the problem of insufficient recognition of existing antibodies in immunohistochemical detection is solved, and effective recognition and detection of TROP2 protein is achieved.
Patent Information
- Application Number
- CN202411489095.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-24
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-10-24
AI Technical Summary
The existing anti-TROP2 protein antibodies have problems with insufficient specificity and sensitivity in immunohistochemical assays, making it difficult to effectively identify cells expressing TROP2 protein.
A rabbit monoclonal antibody was developed with the amino acid sequences of heavy chain variable region and light chain variable region of SEQ ID NO.1 and SEQ ID NO.2, and the TROP2 protein fragment was recombinantly expressed by E. coli and bound to the HIS protein tag. Used to prepare antibodies and perform immunohistochemical detection by antigens from immune rabbits.
Antibodies that recognize TROP2 protein with high specificity and sensitivity are provided for immunological detection, especially in immunohistochemical assays that can clearly identify cells expressing TROP2 protein, which is better than the performance of commercially available antibodies.
Smart Images

Figure CN119060187A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical engineering, and in particular to an anti-TROP2 protein monoclonal antibody and a preparation method and application thereof. Background Art
[0002] TROP2 is a member of the B7 family of co-stimulatory molecules and one of the immune checkpoint molecules of the B7-CD28 family. It plays an important role in T cell-mediated immune responses. TROP2 protein is not expressed or is extremely low in normal tissues and cells, but is abnormally expressed in a variety of malignant tumors and is closely related to tumor progression and patient prognosis. The TROP2 protein molecule is a type I transmembrane protein encoding 316 amino acids, containing 7 exons and 6 introns. In addition, there are two major splice forms of TROP2 protein, TROP2a (2Ig-TROP2) whose extracellular segment is composed of Ig-V-IgC and B7-H3b (4Ig-TROP2) whose extracellular segment is composed of Ig-V-IgC-Ig-V-IgC. Humans mainly express 4Ig-TROP2.
[0003] The role of TROP2 in tumor immunity is controversial. On the one hand, it can play a co-stimulatory role, stimulating the proliferation of CD4 and CD8 T cells and the secretion of cytokines such as IFN-γ, IL-8 and TNF-α, thereby improving the body's immune response to tumors. On the other hand, it can inhibit the activation of CD4+ T cells and the production of cytokines such as IFN-γ and IL-4, thus playing a co-inhibitory role.
[0004] Studies have confirmed that the expression level of TROP2 is closely related to the occurrence, proliferation, metastasis and invasion, metabolism and tumor angiogenesis of malignant tumors. Existing immunohistochemical results have shown that B7-H3 is highly expressed in various cancer tissues such as liver cancer, colorectal cancer, endometrial cancer, breast cancer, bile duct cancer, colorectal cancer, etc., and is significantly correlated with the degree of tumor infiltration, distant metastasis and differentiation. Summary of the invention
[0005] The inventors provide an anti-TROP2 protein monoclonal antibody, wherein the amino acid sequence of the heavy chain variable region of the monoclonal antibody is the amino acid sequence shown in SEQ ID NO.1; the amino acid sequence of the light chain variable region of the monoclonal antibody is the amino acid sequence shown in SEQ ID NO.2.
[0006] Furthermore, the monoclonal antibody specifically recognizes TROP2 protein.
[0007] Furthermore, the monoclonal antibody is a rabbit monoclonal antibody.
[0008] Furthermore, the clone number of the rabbit monoclonal antibody is T1815162.
[0009] The inventors also provide a method for preparing an anti-TROP2 protein monoclonal antibody, wherein the antigen used to immunize rabbits is a recombinant protein, and the recombinant protein is recombinantly expressed by Escherichia coli.
[0010] Furthermore, the recombinant protein comprises a TROP2 protein fragment and a HIS protein tag.
[0011] Furthermore, the TROP2 protein fragment is the amino acid sequence shown in SEQ ID NO.3.
[0012] Furthermore, the plasmid vector selected in the recombination process is pCMV3.
[0013] The inventors also provide a TROP2 protein immunoassay reagent, which contains the above-mentioned anti-TROP2 protein monoclonal antibody as its effective ingredient.
[0014] Different from the prior art, the beneficial technical effects of the present invention are as follows: the above technical solution provides an anti-TROP2 protein rabbit monoclonal antibody, the amino acid sequence of the heavy chain variable region of the monoclonal antibody is the amino acid sequence shown in SEQ ID NO.1; the amino acid sequence of the light chain variable region of the monoclonal antibody is the amino acid sequence shown in SEQ ID NO.2. The antibody has high specificity and sensitivity, can specifically identify cells expressing TROP2 protein, and is suitable for immunological detection, especially immunohistochemical detection. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 The figure is a comparison of the immunohistochemical staining results of a case of breast ductal invasive carcinoma (the right one is the rabbit monoclonal antibody TROP2 of the present invention, and the left one is the commercially available TROP2).
[0016] Figure 2 The figure is a comparison of the immunohistochemical staining results of gallbladder tissue (the right one is the rabbit monoclonal antibody TROP2 of the present invention, and the left one is the commercially available TROP2). DETAILED DESCRIPTION
[0017] In order to explain in detail the possible application scenarios, technical principles, specific schemes that can be implemented, and the purposes and effects that can be achieved, the following is a detailed description of the specific embodiments listed in conjunction with the accompanying drawings. The embodiments described herein are only used to more clearly illustrate the technical solutions of the present application, and are therefore only used as examples, and cannot be used to limit the scope of protection of the present application.
[0018] Reference to "embodiment" herein means that the specific features, structures or characteristics described in conjunction with the embodiment may be included in at least one embodiment of the present application. The term "embodiment" appearing in various places in the specification does not necessarily refer to the same embodiment, nor does it particularly limit its independence or association with other embodiments. In principle, in the present application, as long as there is no technical contradiction or conflict, the various technical features mentioned in the embodiments can be combined in any way to form a corresponding implementable technical solution.
[0019] Unless otherwise defined, the technical terms used in this document have the same meanings as those generally understood by those skilled in the art to which this application belongs; the use of relevant terms in this document is only for describing specific embodiments and is not intended to limit this application.
[0020] In the description of this application, the term "and / or" is an expression used to describe the logical relationship between objects, indicating that three relationships may exist, for example, A and / or B, which means: A exists, B exists, and A and B exist at the same time. In addition, the character " / " in this article generally indicates that the objects before and after are in an "or" logical relationship.
[0021] In the present application, terms such as “first” and “second” are merely used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any actual relationship of quantity, priority or sequence between these entities or operations.
[0022] Without further limitations, in this application, the words "include", "comprises", "has" or other similar expressions used in the sentences are intended to cover non-exclusive inclusion. These expressions do not exclude the presence of additional elements in the process, method or product including the elements, so that the process, method or product including a series of elements may include not only those limited elements, but also other elements not explicitly listed, or also include elements inherent to such process, method or product.
[0023] Similar to the understanding in the Examination Guidelines, in this application, expressions such as "greater than", "less than", "exceed" and the like are understood to exclude the number itself; expressions such as "above", "below", "within" and the like are understood to include the number itself. In addition, in the description of the embodiments of this application, "multiple" means more than two (including two), and similar expressions related to "multiple" are also understood in this way, such as "multiple groups", "multiple times", etc., unless otherwise clearly and specifically limited.
[0024] Example 1 Preparation of recombinant TROP2 protein fragments
[0025] 1. Gene Optimization and Synthesis
[0026] According to the protein sequence of TROP2 with accession number NP_002344.2 in the NCBI database, protein fragments at sites 27-274 and 299-323 were selected, directly optimized into gene fragments suitable for expression in E. coli Rosetta (DE3), and cloned into the pCMV3 vector.
[0027] The expression vector was used to transform competent E. coli cells E. coli Rosetta (DE3), and clones on the plate were selected for inoculation and PCR identification of the bacterial solution was performed. The clones with positive PCR results were selected for sequencing analysis, and the clones with completely correct sequences were used.
[0028] Choosing different antigens for immunization may produce antibodies with different binding properties. The molecule also has multiple variants caused by variable shearing, which ultimately leads to different recognition capabilities and patterns of different antibodies for antigen-expressing cells. TROP2 molecules are analyzed according to the published sequence. Based on the structure, antigenicity, hydrophilicity and hydrophobicity of the constituent amino acids and the secondary structure, the region suitable for soluble expression and good immunogenicity is selected for recombinant expression. The gene sequence of sites 27-274 and 299-323 of TROP2 is selected for codon optimization, and the molecular weight is about 36kDa. TROP2 protein is obtained by sequence optimization design using prokaryotic expression gene sequences. The recombinant immunogen consists of an antigenic TROP2 protein fragment and a protein tag for recombinant protein purification, and the protein tag is HIS.
[0029] 2. Protein Expression and Purification
[0030] The overnight bacteria cultured from a single colony were transferred to 100 mL LB medium at a ratio of 1:100, and ampicillin with a final concentration of 100 μg / mL was added. The culture was shaken at 37°C until OD600 was 0.6-0.8, and 0.8 mmol / L IPTG was added. The culture was shaken at 37°C for 4 hours, and the bacteria were ultrasonically broken after harvesting. The recombinant protein was labeled with histidine and affinity purified using a nickel column. Elution was performed with 150 mmol / L imidazole, and SDS PAGE separation and detection were performed. The PCMV3-TROP2 (27-274 and 299-323aa) was expressed in the supernatant and purified to a protein concentration of 1 mg / mL, with a purity of 85%, meeting the requirements for animal immunization and antibody screening and identification.
[0031] Example 2 Isolation of single B cells producing rabbit anti-human TROP2 monoclonal antibodies
[0032] 1. Immunity and ELISA testing
[0033] The recombinant TROP2 protein in Example 1 was emulsified with Freund's complete adjuvant, and 6 rabbits were selected for immunization at a dose of 300 μg / rabbit. Reinforced immunization was performed once on the 21st, 28th, and 49th days, and the antigen was emulsified with Freund's incomplete adjuvant at a dose of 150 μg / rabbit. After the third immunization, the serum ELISA titer was tested, and the immune titer of rabbit A was greater than 1:2.56K, and the immune effect met the requirements. The sera of 4 rabbits from the fourth immunization were tested by IHC, and according to the results (i.e., the positive pair photos corresponding to the antibody were used for detection, and immunohistochemical staining could be observed on the corresponding detection sites in the positive pair photos), one of the rabbits (number: A) was selected for subsequent monoclonal antibody screening.
[0034] 2. Spleen Cell Isolation and B Lymphocyte Sorting
[0035] Monoclonal antibodies were prepared for the selected rabbits. The spleen was taken 3 days after the final immunization. The spleen of the rabbit was placed in RMPI basal medium containing 100U / mL penicillin and 100ug / mL streptomycin, cut into pieces with a surgical blade and transferred to a 100μm cell screen for grinding. The obtained cell suspension was filtered to remove large cell clumps and tissue capsules, and the supernatant was removed after centrifugation at 400g for 5 minutes to retain the spleen cell mass. The spleen cell mass was resuspended with a hypotonic solution and the red blood cells were lysed and centrifuged again at 400g for 5 minutes to retain the spleen cells. The spleen cells were resuspended with RMPI basal medium containing 100U / mL penicillin and 100μg / mL streptomycin, centrifuged at 400g for 5 minutes, and the obtained spleen cells were resuspended with complete medium (RMPI basal medium containing 10% fetal bovine serum, 100U / mL penicillin and 100μg / mL streptomycin) for use.
[0036] For the specific steps of B lymphocyte sorting, please refer to Chinese Patent 201910125091.4 "Method for Efficiently Isolating Single Antigen-Specific B Lymphocytes from Spleen Cells".
[0037] About 2000 single B cell clones were sorted and cultured, and positive clones that specifically recognized the recombinant TROP2 protein in Example 1 were initially screened out by ELISA. Based on the ELISA data, 50 supernatants from high to low were selected for IHC verification.
[0038] 3. B cell culture positive clone detection
[0039] IHC validation was performed on single B cell culture supernatant using multiple tumor tissue chips and normal tissue chips containing TROP2 positive and negative samples. Among them, the IHC results of the culture supernatant of 8 clones were good, so LEM supernatant was prepared for IHC validation to identify clones with excellent sensitivity and specificity (T1815162).
[0040] The screening criteria for sensitivity and specificity are: when testing with the positive control photo corresponding to the antibody, immunohistochemical staining can be observed at the corresponding test site in the positive control photo, while no immunohistochemical staining is observed at the non-test site. Compared with the control antibody, the staining intensity reaches or even exceeds that of the control antibody.
[0041] IV. Cloning of the gene encoding rabbit monoclonal antibody (T1815162) and construction of rabbit monoclonal antibody expression plasmid
[0042] After the cells of the positive clones are collected and lysed, RNA is extracted and reverse transcribed into cDNA. Using the PCR method, the naturally paired rabbit monoclonal antibody light and heavy chain variable region genes are amplified from the cDNA of the corresponding positive clones and sequenced. The rabbit monoclonal antibody expression vector plasmids are constructed using the above naturally paired rabbit monoclonal antibody light and heavy chain variable region gene sequences.
[0043] Example 2 was completed by Fuzhou Maixin Biotechnology Development Co., Ltd. on behalf of Dima Biotechnology (Wuhan) Co., Ltd., in which Fuzhou Maixin Biotechnology Development Co., Ltd. performed immunohistochemical screening.
[0044] Example 3 TROP2 rabbit monoclonal antibody expression
[0045] 1. Plasmid Amplification and Extraction
[0046] Take out a tube (100 μL) of competent bacteria (DH5α), insert it on ice, and place it on ice for 5-10 minutes; add 5 μL of plasmid, shake it gently, and place it on ice for 30 minutes; shake it gently and place it in a 42°C water bath for 90 seconds for heat shock, then quickly put it back in ice and let it stand for 5 minutes; add 800 μL of LB culture medium (note: without antibiotics) to the above in the clean bench, mix it gently, and fix it on a shaker for 37°C and shake it for 1 hour; take 50-100 μL of the above transformation mixture in the clean bench, drop it into the marked solid LB flat plate culture dish containing Amp, and spread it evenly with a glass coating rod (sterilized); first place it upright in a 37°C incubator for 30 minutes to allow the bacterial solution on the surface to completely penetrate into the culture medium, and then invert it and place it in a 37°C incubator for overnight culture. Use a pipette to pick up a single colony and place it into 4 mL of LB medium (containing 2 uL of 200 mg / mL Amp), and culture it in a shaking incubator at 37°C for 16 h, at 37°C and 220 rpm.
[0047] Add 1 mL of bacterial solution to 100 mL of LB medium (containing 50 μL of 200 mg / mL Amp) and culture at 37°C in a shaking incubator for 16 h. Use SanPrep Endotoxin-Free Plasmid DNA Extraction Kit (Sangong) to extract plasmids according to the instructions.
[0048] 2. Transfection
[0049] Adjust the concentration of 293F cells to 2.5-3×10 cells / mL using Expi293FTM Expression Medium. 6 viable cells / mL and cultured overnight.
[0050] 1) Count the live cells using a hemocytometer. The live cell concentration is about 4.5-5.5×10 6 viable cells / mL, and the number of viable cells must meet the requirements of the expression system;
[0051] 2) Dilute the cells to a concentration of 3 × 10 cells / mL using Expi293FTM Expression Medium. 6 viable cells / mL;
[0052] 3) Add the plasmid DNA to Opti-MENTM I Ruduced Serum Medium, pipette gently, and invert to mix;
[0053] 4) Gently invert ExpiFectamine TM 293 Reagent 4-5 times, ExpiFectamine TM 293 Mix Reagent and Opti-MENTM I Ruduced Serum Medium, gently pipette and invert 2-3 times, and leave at room temperature for 5 minutes;
[0054] 5) Mix the solutions of step 3) and 4) by gently blowing and inverting 2-3 times to mix well;
[0055] 6) placing the solution of step 5) at room temperature for 10-20 minutes;
[0056] 7) Slowly pipette the mixture into the cell culture medium and gently shake the flask;
[0057] 8) 8% CO 2 , cultured in a shaking incubator at 37°C for 5-7 days;
[0058] 9) After 18-22 hours, add ExpiFectamine TM 293 Transfection Enhancer1 and ExpiFectamine TM 293 Transfection Enhancer2 (Note: Mix in advance before use), shake gently to mix, and continue culturing.
[0059] 3. Purification of Monoclonal Antibodies
[0060] The antibody was purified from the supernatant using HiTrap rProtein A FF affinity chromatography according to the instructions. The purity was determined by SDS-PAGE gel and the concentration was determined by Bradford method. The purified antibody was stored at -20°C. Example 4. Immunohistochemical tissue chip staining and identification
[0061] 1. Chip preparation process
[0062] Each sample was first stained with HE slices to determine the tumor site. Circle the tumor target site and prepare for punching. When making a blank receptor wax block, place the plastic frame on the mold, pour the melted paraffin (melting point at 55-58°C) into the mold, cool to room temperature, put the mold into a -20°C refrigerator for 6 minutes, and take the wax block out of the mold. Select a 1mm diameter sample needle on the tissue sample machine to punch a hole in the receptor wax block with a hole depth of 3-4mm. Use another 1mm diameter punching needle to punch a hole in the marked part of the wax block to collect the tissue core, and its length is about 0.1mm shallower than the hole depth of the receptor wax block. Insert the collected tissue core directly or carefully pick it up with tweezers and insert it into the empty hole of the receptor wax block. Repeat this process until all sample points are prepared. Finally, press all tissue cores flat with a glass slide to make the tissue chip wax block flat and smooth. The prepared tissue chip wax block is put into the wax block mold, and then placed in a 60℃ oven for 15 minutes to melt the wax of the tissue core and the receptor wax block. Then the mold is gently removed from the oven, and the semi-melted paraffin is cooled at room temperature for about 30 minutes. Then it is placed in a -20℃ refrigerator for 6 minutes, and then the tissue chip wax block is removed from the mold, sliced or placed in a 4℃ refrigerator for later use. After trimming, continuous slices are made, and the thickness is set to 3μm. The continuous slices are floated in cold water and allowed to unfold naturally. Then the separated slices are transferred to 45℃ warm water for 30 seconds, and the slices are mounted on a slide treated with poly-lysine. The prepared tissue chip is placed in a 65℃ oven for 2 hours, taken out to cool at room temperature, and stored in a -4℃ refrigerator.
[0063] II. IHC staining and analysis
[0064] Dewax in xylene for 3 times, 6 minutes each time, hydrate in 100%, 100%, 95%, 85% graded ethanol, 3 minutes each time, and finally rinse with tap water. Perform antigen repair, then place the sections in a wet box and rinse with PBS for 3×3 minutes. Add 3% H 2 O 2Incubate for 10 minutes, rinse with PBS for 3×3 minutes. Shake dry the slices, add the primary antibody diluted in an appropriate ratio (the dilution ratio of the antibody is designed according to the antibody concentration for the first dilution), incubate at room temperature (25°C) for 1 hour, rinse with PBS for 3×3 minutes, add the secondary antibody and incubate at room temperature for 15-30 minutes, rinse with PBS for 3×3 minutes, shake off the PBS, and use freshly prepared DAB color developing solution for 3-10 minutes. Counterstain with hematoxylin for 25 seconds, and return to blue with PBS for 30 seconds. Dehydrate in a gradient of 85% (3 minutes)-95% (3 minutes)-100% (3 minutes)-100% (3 minutes) alcohol, and finally transparentize with xylene for 3 minutes and seal with neutral gum.
[0065] Immunohistochemical staining results are divided into: positive and negative. Positive expression must be in specific antigenic sites of cells and tissues to be considered positive. In the case of clear tissue staining distribution and accurate cell localization, the staining results are further divided according to the difference in staining intensity, as follows:
[0066] 1. The sample is weakly positive; marked as "+";
[0067] 2. The sample is moderately positive; marked as "++";
[0068] 3. The sample is highly positive; marked as "+++".
[0069] 4. The sample is negative and marked as “-”.
[0070] 3. Data Statistics
[0071] 1. Tumor tissue chip test results:
[0072] The antibody TROP2 (T1815162) of the present invention and the commercially available antibody TROP2 (rabbit polyclonal antibody) were used to simultaneously detect 49 cases of breast ductal invasive carcinoma and the test results were compared. The immunohistochemical results of TROP2 were statistically analyzed. The whole test process adopted a double-blind design, and the statistical results are shown in the following table:
[0073]
[0074] The results showed that the rabbit monoclonal antibody TROP2 (T1815162) had accurate staining positioning, clear staining without nonspecific staining, and a clean background. In immunohistochemical detection, the positive rate was comparable to that of commercially available antibodies, and there were 15 cases where the positive intensity of the TROP2 rabbit monoclonal antibody was higher than that of the commercially available antibody, indicating that the sensitivity of the rabbit monoclonal antibody TROP2 (T1815162) was higher than that of the commercially available antibody.
[0075] Figure 1 The figure is a comparison of the immunohistochemical staining results of a case of breast ductal invasive carcinoma (the left one is the rabbit monoclonal antibody TROP2 of the present invention, and the right one is the commercially available TROP2).
[0076] 2. Normal tissue chip test results:
[0077] The normal tissue array includes 30 normal tissue samples, which are mainly selected from fresh and timely fixed surgical specimens; each tissue includes 3 different case samples. The 30 normal tissues include: brain, heart, cerebellum, esophagus, adrenal gland, stomach, ovary, small intestine, pancreas, colorectum, parathyroid gland, liver, pituitary gland, salivary gland, testis, kidney, thyroid gland, prostate gland, breast, uterus, spleen, bladder, tonsil, skeletal muscle, thymus (infants), skin, bone marrow, peripheral nerve, lung, and mesothelial cells.
[0078] The rabbit monoclonal antibody TROP2 (T1815162) and the commercially available TROP2 antibody were simultaneously detected on normal tissue chips, and the positive and negative test results were consistent, indicating that the specificity of the antibody in normal tissues is equivalent to that of the commercially available antibody. Figure 2 The figure is a comparison of the immunohistochemical staining results of gallbladder tissue (the left one is the rabbit monoclonal antibody TROP2 of the present invention, and the right one is the commercially available TROP2).
[0079] Finally, it should be noted that although the above embodiments have been described in the specification and drawings of this application, this does not limit the scope of patent protection of this application. All technical solutions generated by replacing or modifying equivalent structures or equivalent processes based on the essential concept of this application using the contents recorded in the specification and drawings of this application, as well as directly or indirectly implementing the technical solutions of the above embodiments in other related technical fields, are included in the scope of patent protection of this application.
Claims
1. An anti-TROP2 protein monoclonal antibody, characterized in that: The amino acid sequence of the heavy chain variable region of the monoclonal antibody is the amino acid sequence shown in SEQ ID NO.1; the amino acid sequence of the light chain variable region of the monoclonal antibody is the amino acid sequence shown in SEQ ID NO.
2.
2. The monoclonal antibody according to claim 1, characterized in that The monoclonal antibody is a rabbit monoclonal antibody with clone number T1815162.
3. A method for preparing an anti-TROP2 protein monoclonal antibody, characterized in that: The antigen used to immunize the rabbit is a recombinant protein, which is recombinantly expressed by Escherichia coli.
4. The preparation method according to claim 3, characterized in that: The recombinant protein comprises a TROP2 protein fragment and a HIS protein tag.
5. The preparation method according to claim 3, characterized in that: The TROP2 protein fragment is the amino acid sequence shown in SEQ ID NO.
3.
6. The preparation method according to claim 3, characterized in that: The plasmid vector used in the recombination process was pCMV3.
7. A TROP2 protein immunoassay reagent, characterized in that: The immunoassay reagent contains the anti-TROP2 protein monoclonal antibody according to claim 1 as its effective ingredient.
8. The immunoassay reagent according to claim 7, characterized in that: The immunoassay includes immunohistochemistry, immunoblotting and enzyme-linked immunosorbent assay.
Citation Information
Patent Citations
Anti-TROP2 antibody and application thereof
CN112500484A
Monoclonal antibody of anti-Trop2 protein and application thereof
CN116789835A
Antibodies binding trop2 and uses thereof
US20240207432A1
Trop2 antibody, preparation method therefor, and conjugate and use thereof
WO2021027851A1
